Oppenheimer raised the firm’s price target on Prestige Consumer (PBH) to $93 from $87 and keeps an Outperform rating on the shares after meetings with senior management. The company does not comment on intra-quarter business trends. Overall, the firm walked away still confident with its bullish view and longer-term thesis. The tone of management remained constructive on the company’s shorter- and longer-term prospects.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PBH:
- Prestige Consumer price target raised to $104 from $95 at DA Davidson
- What’s in Your Medicine Cabinet? It’s likely Prestige Consumer Healthcare (PBH) Products
- Prestige Consumer Healthcare Reports Record Earnings Despite Challenges
- Prestige Consumer price target raised to $100 from $93 at Canaccord
- Prestige Consumer Healthcare Reports Stable Earnings Growth